Related Experiment Videos
[Therapeutic approach to chronic hepatitis B and C in the dawn of the third millenium]
1Service de Gastro-Entérologie et d'Hépato-Pancréatologie, Hôpital Erasme, U.L.B.
Insights
This review covers the latest on hepatitis B and C virus infections, emphasizing vaccination and screening. Early detection and management are key to preventing severe liver disease and its complications.
Area of Science:
- Hepatology
- Virology
- Infectious Diseases
Context:
- Chronic liver disease is a significant global health concern.
- Hepatitis B and C virus infections are leading causes of liver disease.
- Advances in understanding viral pathogenesis and natural history are crucial.
Purpose:
- To illustrate recent advancements in the epidemiology, pathogenesis, and natural history of hepatitis B and C virus infections.
- To present practical management strategies for patients with chronic hepatitis B and C liver disease.
- To advocate for universal hepatitis B vaccination and risk-based screening for hepatitis B and C.
Summary:
- The review details current knowledge on hepatitis B and C virus infections, including their epidemiological trends, disease mechanisms, and disease progression.
- It outlines effective patient management approaches for chronic liver conditions caused by these viruses.
- Recommendations include promoting universal hepatitis B vaccination and screening at-risk populations for hepatitis B and C.
Impact:
- Reducing morbidity and mortality associated with liver disease and its complications through vaccination and early intervention.
- Empowering patients with knowledge of their evolving risks and available therapeutic options.
- Improving public health outcomes by controlling the spread and impact of hepatitis B and C virus infections.
Abstract:
We try to illustrate the latest developments in epidemiology, pathogenesis and natural history of hepatitis B and C virus infection. Practical management of the patient with chronic B and C liver disease is presented. Universal hepatitis B vaccination should be encouraged in order to reduce to zero morbidity and mortality attributable to liver disease and its complications. Patients at risk for hepatitis B or C infection should be screened and notified about their evolutive risk and the therapeutic possibilities.